<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866824</url>
  </required_header>
  <id_info>
    <org_study_id>2018-55</org_study_id>
    <secondary_id>2018-A02497-48</secondary_id>
    <nct_id>NCT03866824</nct_id>
  </id_info>
  <brief_title>MENIPREP STUDY : EVALUATION OF THE EFFECTIVENESS OF PRP INJECTION IN THE MANAGEMENT OF DEGENERATIVE MENISCAL LESIONS: RANDOMIZED CONTROLLED TRIAL DOUBLE BLIND VERSUS REFERENCE TREATMENT&quot;</brief_title>
  <acronym>MENIPREP</acronym>
  <official_title>MENIPREP STUDY : EVALUATION OF THE EFFECTIVENESS OF PRP INJECTION IN THE MANAGEMENT OF DEGENERATIVE MENISCAL LESIONS: RANDOMIZED CONTROLLED TRIAL DOUBLE BLIND VERSUS REFERENCE TREATMENT&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meniscal tissue has very limited intrinsic properties in terms of repair, given the low
      mitotic activity of chondrocytes and poor vascularization. Nevertheless, its capacity for
      regeneration, in vivo and in vitro, can be stimulated by the contribution of growth factors,
      as has been widely described in the medical and scientific literature. Platelet Enhanced
      Plasma (PRP) is an autologous biological product (that is, derived from the patient's blood)
      containing a growth factor concentrate. The contribution of these growth factors stimulates
      cartilage repair by stimulating neovascularization, collagen synthesis and activation of
      chondrocytes. Intra-articular injection PRP is an autologous biological product, now used in
      daily practice for the treatment of early osteoarthritic lesions.

      The hypothesis of this work is that the injection of PRP in contact with LMD(Degenerative
      Meniscal Lesions) will improve the clinical symptomatology of our patients compared to
      reference treatment (intra-auricular injection of corticosteroids).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CONTROL by Magnetic Resonance Imaging (MIR)</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the evolution of the LMD compared to pretherapeutic images.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>self-completed questionnaire EVA SCORE</measure>
    <time_frame>12 Months</time_frame>
    <description>EVA (analogical visual scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-completed questionnaire SF36</measure>
    <time_frame>12 Months</time_frame>
    <description>SF36 (The Short Form (36) Health Survey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-completed questionnaire KOOS SCORE</measure>
    <time_frame>12 Months</time_frame>
    <description>KOOS (Knee Injury and Osteoarthritis Outcome Score)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>DEGENERATIVE MENISCAL LESIONS</condition>
  <arm_group>
    <arm_group_label>PRP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reference treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of Platelet Enhanced Plasma(PRP)</intervention_name>
    <description>intra-articular injection</description>
    <arm_group_label>PRP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of corticosteroids</intervention_name>
    <description>intra-articular injection</description>
    <arm_group_label>reference treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RMI</intervention_name>
    <description>A CONTROL RMI at 1 year follow-up.</description>
    <arm_group_label>PRP group</arm_group_label>
    <arm_group_label>reference treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women aged 20 to 80

          -  MDD diagnosis objected to MRI (grade II/III)

          -  Joint pain for more than 3 month

          -  Absence of bone lesion or moderate knee osteoarthritis stage &lt;2 on the Kellgren
             Laurence scale (objectified on radiography in schuss) in the 6 months prior to
             inclusion

          -  Axial deformity of the lower limbs less than or equal to 5 °

          -  Signed consent signed by the patient

          -  Ability to perform procedures as part of the follow-up (walk 50 steps on a flat
             surface and up / down stairs).

          -  Be affiliated to a health insurance scheme

        Exclusion Criteria:

          -  Axial deformity&gt; 5 °

          -  Ligament instability

          -  Major injuries or surgery of the target knee or lateral contralateral knee in the 12
             months preceding the inclusion visit

          -  Ligament reconstruction in the 12 months prior to the inclusion visit

          -  Need a cane or assistance to move

          -  BMI&gt; 35

          -  Thrombocytopenia &lt;150 G / L

          -  Thrombocytosis&gt; 450 G / L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MATTHIEU OLIVIER</last_name>
    <email>matthieu.olivier@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>drci</last_name>
    <phone>0491382747</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

